Systemic treatment for unresectable hepatocellular carcinoma
Hepatocellular carcinoma (HCC) is most commonly found in the context of liver cirrhosis and, in rare cases, in a healthy liver. Its prevalence has risen in recent years, particularly in Western nations, due to the increasing frequency of nonalcoholic fatty liver disease. Advanced HCC has a poor prog...
Saved in:
Main Author: | Leowattana W. |
---|---|
Other Authors: | Mahidol University |
Format: | Review |
Published: |
2023
|
Subjects: | |
Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/82360 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Mahidol University |
Similar Items
-
Survival outcomes of metastatic/unresectable hepatocellular carcinoma in patients treated with sorafenib
by: J. Chantharasamee, et al.
Published: (2020) -
Multi-centre phase II trial of Thalidomide in the treatment of unresectable hepatocellular carcinoma
by: Chuah, B., et al.
Published: (2016) -
Radiofrequency ablation alone versus radiofrequency ablation combined with chemoembolization in unresectable hepatocellular carcinoma
by: Thanongchai Siriapisith, et al.
Published: (2018) -
Phase 2 trial of linifanib (ABT-869) in patients with unresectable or metastatic hepatocellular carcinoma
by: Toh, H.C., et al.
Published: (2014) -
Disease control and failure patterns of unresectable hepatocellular carcinoma following transarterial radioembolization with yttrium-90 microspheres and with/without sorafenib
by: Ajalaya Teyateeti, et al.
Published: (2022)